Peter Meijer sold Novozymes AS (PINK: NVZMY)
Peter Meijer (R-MI), a U.S. Representative, has disclosed 1 trade in Novozymes AS (NVZMY) since 2021, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Peter Meijer sold $1,001 - $15,000 of Novozymes AS (PINK: NVZMY) on February 17, 2021. Since that trade, NVZMY is up +11.82% against the S&P 500 up +103.05%, an outperformance of -91.23%.
Data updated
Peter Meijer's NVZMY trades vs the price
NVZMY is up +11.82% since Peter Meijer sold on February 17, 2021, versus +103.05% for the S&P 500.
Performance since this trade
All Peter Meijer NVZMY trades
Peter Meijer & NVZMY trading FAQ
Is it legal for Peter Meijer to trade Novozymes AS (NVZMY) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Novozymes AS (NVZMY), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Peter Meijer sell NVZMY?
Peter Meijer disclosed a sale of $1,001 - $15,000 of Novozymes AS (NVZMY) on February 17, 2021, according to public STOCK Act filings.
How has NVZMY performed since Peter Meijer's trade?
Since Peter Meijer sold NVZMY on February 17, 2021, the stock is up +11.82%, versus +103.05% for the S&P 500 over the same period, an outperformance of -91.23%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional NVZMY trades?
Quantellect tracks every disclosed congressional trade in Novozymes AS (NVZMY) on the Novozymes AS congressional trading page, which aggregates filings across all members of Congress.
Peter Meijer's NVZMY tradesAll congressional filings for Novozymes ASPeter Meijer's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.